OCT Foundations

AMD: OCT Findings & En Face Correlation

Age-related macular degeneration is the leading cause of irreversible vision loss in adults over 50. OCT has transformed how we detect, stage, and monitor AMD — and en face imaging reveals the full geographic extent of disease that B-scan alone consistently underestimates.

Clinical Impact: Studies show en face imaging reveals AMD lesion areas 40–60% larger than B-scan estimates alone. This difference changes staging, monitoring intervals, AREDS2 supplement counseling, and treatment thresholds.

Dry AMD: The Drusen Foundation

Drusen on B-Scan: Small / Medium / SoftHardMediumLarge soft 125um+under 63um63-125um125um+ = high risk

Drusen size spectrum: hard, medium, large soft, RPE elevation — Educational illustration, not a clinical scan

🔭 Clinical Reference — CC BY 4.0
OCT B-scans of AMD drusen: hard drusen, cuticular drusen, and drusenoid PED

AMD drusen on OCT (Fig.2). Left: hard drusen (small focal RPE elevations). Middle: cuticular drusen (triangular sub-RPE deposits with 'sawtooth' pattern). Right: drusenoid PED (broad, flat RPE elevation with homogeneous fill). — Kulyabin M et al. Sci Data 11:365 (2024), CC BY 4.0

Drusen are deposits between the RPE and Bruch's membrane. On B-scan, they appear as sub-RPE elevations — the RPE is lifted, creating an irregular baseline. Their characteristics carry prognostic weight:

Drusen TypeSize / AppearanceOCT FeatureClinical Risk
Hard drusen<63 μm, discreteSmall, sharp sub-RPE bumpsLower risk
Soft drusen>125 μm, confluentBroad, indistinct marginsHigher progression risk
Drusenoid PEDLarge confluentMound-shaped RPE elevationHigh risk — monitor closely
Reticular pseudo-drusenInner surface depositsSubretinal material above RPEVery high progression risk
Reticular Pseudo-Drusen (RPD): These are above the RPE, not below it — subretinal drusenoid deposits. On B-scan they appear as subtle hyperreflective material between the EZ and RPE. On en face imaging at the outer retinal slab, they appear as a characteristic reticular (net-like) pattern. RPD carry a much higher risk of progression to late AMD and are easily missed without en face views.

Geographic Atrophy (GA)

GA B-Scan: RPE Loss and Choroidal EnhancementNormalEZ absentRPE lostChoroidal signal increasedNormalGA zone: EZ loss + RPE absence + EOPRGrowth rate approx 2 sq mm/year on serial scans

GA: EZ loss, RPE absence, enhanced optical penetrance — Educational illustration, not a clinical scan

GA represents complete loss of the RPE, Bruch's membrane, and overlying photoreceptors. On B-scan, the key features are:

  • RPE loss: The bright RPE band disappears — enhanced light transmission to the choroid creates a characteristic "choroidal hypertransmission" (brighter choroid beneath the atrophic zone)
  • EZ disruption: The ellipsoid zone is absent or severely attenuated over the atrophic area
  • Outer retinal thinning: ONL and photoreceptor layers thin and eventually disappear
  • Junction zone: At the GA border, you can often identify a "junctional zone" where EZ is intact but transitioning

En face imaging at the RPE slab transforms GA assessment: the atrophic area appears as a bright, well-demarcated zone (enhanced choroidal signal through absent RPE). This gives you an accurate lesion area measurement that drives monitoring frequency and trial eligibility decisions.

Wet AMD: Choroidal Neovascularization

CNV Types 1 / 2 / 3 on B-ScanType 1Sub-RPEType 2Sub-retinalSRFType 3Intraretinal NV

CNV type 1 (sub-RPE), type 2 (sub-retinal), type 3 (intraretinal) — Educational illustration, not a clinical scan

🔭 Clinical Reference — CC BY 4.0
OCT B-scans showing subretinal fluid, intraretinal fluid, and sub-RPE fluid in wet AMD

Wet AMD fluid compartments (Fig.3). SRF (subretinal fluid): hyporeflective space between RPE and photoreceptors. IRF (intraretinal fluid): cystoid spaces within retinal layers. Sub-RPE fluid: PED with fibrovascular fill. Each signals active exudation requiring treatment. — Kulyabin M et al. Sci Data 11:365 (2024), CC BY 4.0

CNV represents growth of abnormal vessels from the choroid through Bruch's membrane. On B-scan, the presentation depends on CNV type:

CNV TypeLocationB-scan FeaturesTreatment Urgency
Type 1 (occult)Sub-RPEIrregular RPE elevation, fibrovascular PEDHigh — active leakage
Type 2 (classic)Sub-retinalHyperreflective fibrovascular tissue above RPEHigh — rapid vision loss risk
Type 3 (RAP)IntraretinalIRF + SRF + PED triad; neovascularization grows downwardHigh
MNV (quiescent)Sub-RPEFlat fibrovascular PED, no fluidMonitor — treat when active
The Fluid Triad: Any new combination of SRF (subretinal fluid), IRF (intraretinal fluid), or PED (pigment epithelial detachment) in a patient with known or suspected AMD should raise your index of suspicion for active CNV. Treat the fluid, not just the lesion.

En Face Correlation: The AMD Advantage

AMD En Face CorrelationB-ScanDrusen PEDtoEn Face (RPE slab)Drusen mapGA dark zoneCNV loopEn face enables full spatial extent mapping

B-scan drusen PED to RPE slab en face drusen map — Educational illustration, not a clinical scan

En face views at the RPE and sub-RPE slabs are game-changers for AMD:

  • RPE slab: Drusen appear as bright spots against the normal RPE. GA appears as areas of very bright choroidal signal (transmission defect). Reticular pseudo-drusen form a distinctive reticular pattern.
  • Sub-RPE / Bruch's slab: Type 1 CNV shows as a lacy, irregular bright lesion. Drusenoid PED shows as a large confluent bright area.
  • Outer retina slab: Photoreceptor loss over atrophy creates characteristic dark (low reflectivity) zones that map the functional loss area.

AMD Monitoring Protocol

AMD OCT Monitoring Intervals12Intermediate(annual min)6Soft drusen /RPD / dPED6GA (advanceddry AMD)1Wet AMD(monthly init.)moFellow eye risk:25-50% conversion at 5yr if other eye wetGA growth:~1.7 mm sq/yr avg; serial en face RPE slab tracks areaAREDS2:Re-stage after each en face RPE slab reviewMonths between OCT scans by AMD stage

AMD monitoring: annual to monthly depending on stage — Educational illustration, not a clinical scan

  • Intermediate AMD (medium drusen only): Annual OCT minimum; consider 6-month if soft drusen, RPD, or drusenoid PED
  • Advanced dry AMD / GA: Every 6 months — monitor for wet conversion. GA growth rate ~1.7 mm²/year average but highly variable
  • Treated wet AMD: Follow your treating retinologist's protocol; typically monthly initially, then T&E or PRN
  • Fellow eye with wet AMD: 25–50% 5-year fellow eye conversion risk; minimum every 6 months
Practical Pearl: When staging AMD from OCT, always look at the en face RPE slab before finalizing your staging. The B-scan foveal cut often shows you a small area; the en face slab shows you the full disease extent. One missed quadrant of confluent soft drusen changes your AREDS2 recommendation.

Key Takeaways

  • Drusen type and size predict progression risk — soft drusen and RPD carry the highest risk
  • GA shows as choroidal hypertransmission on B-scan; en face gives accurate lesion area
  • CNV type (1, 2, 3) guides treatment urgency and expectation of response
  • Always assess the en face RPE slab — B-scan alone underestimates disease extent
  • Fellow eye of wet AMD needs minimum 6-month monitoring
Drusen RPE elevation Vitreous ILM/RNFL GCL+IPL INL OPL ONL ELM EZ / IZ RPE / BM Choroid

Educational illustration — Dry AMD B-scan pattern: sub-RPE drusen deposits (amber) with overlying EZ disruption and RPE elevation. Real clinical scans in full course.

Sign up to track your progress and access all lessons.

Create Free Account